¿Cómo interpretar el aumento de la Troponina?

Referencias
1. Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature. Circulation 1979; 59:607–9.
2. Babuin L, Jaffe AS. Troponin: the biomarker of choice for the detection of cardiac injury. CMAJ 2005;173:1191–202.
3. Luepker RV, Apple FS, Christenson RH, et al. Case definitions for acute coronary heart disease in epidemiology and clinical research studies: a statement from the AHA Council on Epidemiology and Prevention; AHA Statistics Committee; World Heart Federation Council on Epidemiology and Prevention; the European Society of Cardiology Working Group on Epidemiology and Prevention; Cen ters for Disease Control and Prevention; and the National Heart, Lung, and Blood Institute. Circulation 2003;108:2543–9.
4. Heidenreich PA, Alloggiamento T, Melsop K, et al. The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: a meta-analysis. J Am Coll Cardiol 2001;38:478 – 85.
5. Ottani F, Galvani M, Nicolini FA, et al. Elevated cardiac troponin levels predict the risk of adverse outcome in patients with acute coronary syndromes. Am Heart J 2000;140:917–27.
6. Antman EM, Tanasijevic MJ, Thompson B, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996;335:1342–9.
7. Morrow DA, Rifai N, Tanasijevic MJ, et al. Clinical efficacy of three assays for cardiac troponin I for risk stratification in acute coronary syndromes: a Thrombolysis In Myocardial Infarction (TIMI) 11B Substudy. Clin Chem 2000;46:453– 60.
8. Hamm CW, Heeschen C, Goldmann B, et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. N Engl J Med 1999; 340:1623–9.
9. Ohman EM, Armstrong PW, Christenson RH, et al. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. N Engl J Med 1996;335:1333– 41.
10. Alpert JS, Thygesen K, Antman E, et al. Myocardial infarction redefined: a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000;36: 959–69
11. Morrow DA, Cannon CP, Jesse RL, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Clin Chem 2007;53:552–74.
12. Thygesen K, Alpert JS, White HD, on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the redefinition of myocardial infarction. Universal definition of myocardial infarction. J Am Coll Cardiol 2007;50:2173–95.
13. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol 2012;60:1581–98.
14. Panteghini M, Pagani F, Yeo KT, et al. Evaluation of imprecision for cardiac troponin assays at low-range concentrations. Clin Chem 2004;50:327–32.
15. Apple FS, Jesse RL, Newby LK, et al. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: analytical issues for biochemical markers of acute coronary syndromes. Clin Chem 2007;53:547–51.
16. Apple FS. A new season for cardiac troponin assays: it’s time to keep a scorecard. Clin Chem 2009;55:1303– 6.
17. Diamond GA, Forrester JS. Analysis of probability as an aid in the clinical diagnosis of coronary-artery disease. N Engl J Med 1979;300: 1350 – 8.
18. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non–ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non–ST-Elevation Myocardial Infarction). J Am Coll Cardiol 2007;50:e1–157.
19. Diamond GA, Kaul S. How would the Reverend Bayes interpret high-sensitivity troponin? Circulation 2010;121:1172–5.
20. Alcalai R, Planer D, Culhaoglu A, et al. Acute coronary syndrome vs nonspecific troponin elevation: clinical predictors and survival analysis. Arch Intern Med 2007;167:276 – 81.
21. Morrow DA, Wiviott SD, White HD, et al. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an appli cation of the classification system from the universal definition of myocardial infarction. Circulation 2009;119:2758 – 64.
22. Newby LK, Roe MT, Chen AY, et al. Frequency and clinical implications of discordant creatine kinase-MB and troponin measurements in acute coronary syndromes. J Am Coll Cardiol 2006;47: 312– 8.
23. Rao SV, Ohman EM, Granger CB, et al. Prognostic value of isolated troponin elevation across the spectrum of chest pain syndromes. Am J Cardiol 2003;91:936 – 40.
24. Newby LK, Christenson RH, Ohman EM, et al., The GUSTO-IIa Investigators. Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes. Circulation 1998;98:1853–9.
25. Benamer H, Steg PG, Benessiano J, et al. Elevated cardiac troponin I predicts a high-risk angiographic anatomy of the culprit lesion in unstable angina. Am Heart J 1999;137:815–20.  Heeschen C, Hamm CW, Goldmann B, et al., PRISM Study Investigators. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. Platelet Receptor Inhibition in Ischemic Syndrome Management. Lancet 1999;354:1757– 62.
26. Heeschen C, Hamm CW, Goldmann B, et al., PRISM Study Investigators. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. Platelet Receptor Inhibition in Ischemic Syndrome Man-agement. Lancet 1999;354:1757– 62.
27. Lindahl B, Diderholm E, Lagerqvist B, et al. Mechanisms behind the prognostic value of troponin T in unstable coronary artery disease: a FRISC II substudy. J Am Coll Cardiol 2001;38:979 – 86.
28.Kastrati A, Mehilli J, Neumann FJ, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 2006;295:1531– 8.
29. Newby LK, Ohman EM, Christenson RH, et al. Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes
30. Lindahl B, Venge P, Wallentin L, Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. J Am Coll Cardiol 1997;29:43– 8.
31. Morrow DA, Antman EM, Tanasijevic M, et al. Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudy. J Am Coll Cardiol 2000;36: 1812–7.
32. Morrow DA, Cannon CP, Rifai N, et al. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarc-tion: results from a randomized trial. JAMA 2001;286:2405–12.
33. Simoons ML. Effect of glycoprotein IIb/IIIa receptor blocker abcix-imab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomized trial. Lancet 2001;357:1915–24.
34. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494 –502.
35. de Winter RJ, Windhausen F, Cornel JH, et al. Early invasive versus selectively invasive management for acute coronary syndromes. N Engl J Med 2005;353:1095–104.
36. Mehta SR, Cannon CP, Fox KA, et al. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA 2005;293:2908 –17.
37. O’Donoghue M, Boden WE, Braunwald E, et al. Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis. JAMA 2008;300:71– 8038.
38. Diderholm E, Andren B, Frostfeldt G, et al. The prognostic and therapeutic implications of increased troponin T levels and ST depression in unstable coronary artery disease: the FRISC II invasive troponin T electrocardiogram substudy. Am Heart J 2002;143: 760 –7.
39. Fox KA, Poole-Wilson P, Clayton TC, et al. 5-year outcome of an interventional strategy in non-ST-elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised trial. Lancet 2005;366:914 –20.
40. Keller T, Zeller T, Peetz D, et al. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med 2009;361: 868 –77.
41. Reichlin T, Hochholzer W, Bassetti S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 2009;361:858 – 67.
42. Latini R, Masson S, Anand IS, et al. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation 2007;116:1242–9.
43. Omland T, de Lemos JA, Sabatine MS, et al. A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med 2009;361:2538 – 47.
44. Morrow DA. Clinical application of sensitive troponin assays.N Engl J Med 2009;361:913–5.
45. Goldberg RJ, Spencer FA, Fox KA, et al. Prehospital delay in patients with acute coronary syndromes (from the global registry of acute coronary events [GRACE]). Am J Cardiol 2009;103:598 – 603.
46. Urban P, Radovanovic D, Erne P, et al. Impact of changing definitions for myocardial infarction: a report from the AMIS registry. Am J Med 2008;121:1065–71.
47. Morrow DA, Rifai N, Sabatine MS, et al. Evaluation of the AccuTnI cardiac troponin I assay for risk assessment in acute coronary syndromes. Clin Chem 2003;49:1396 – 8.
48. Venge P, Johnston N, Lindahl B, et al. Normal plasma levels of cardiac troponin I measured by the high-sensitivity cardiac troponin I access prototype assay and the impact on the diagnosis of myocar dial ischemia. J Am Coll Cardiol 2009;54:1165–72.
49. Anand IS, Kempf T, Rector TS, et al. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation 2010;122:1387–95.
50. de Lemos JA, Drazner MH, Omland T, et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA 2010;304:2503–12.
51. deFilippi CR, de Lemos JA, Christenson RH, et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA 2010;304:2494 –502.
52. Blankenberg S, Zeller T, Saarela O, et al. Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. Circulation 2010;121:2388 –97.
53. Melberg T, Burman R, Dickstein K. The impact of the 2007 ESC/ACC/AHA/WHF universal definition on the incidence and classification of acute myocardial infarction: a retrospective study. Int J Cardiol 2010;139:228 –33.
54. Saiki A, Iwase M, Takeichi Y, et al. Diversity of the elevation of serum cardiac troponin I levels in patients during their first visit to the emergency room. Circ J 2007;71:1458 – 62.
55. Kontos MC, Anderson FP, Ornato JP, et al. Utility of troponin I in patients with cocaine-associated chest pain. Acad Emerg Med 2002;9:1007–13.
56. Kontos MC, Jesse RL, Tatum JL, et al. Coronary angiographic findings in patients with cocaine-associated chest pain. J Emerg Med 2003;24:9 –13.
57. Mahajan N, Mehta Y, Rose M, et al. Elevated troponin level is not synonymous with myocardial infarction. Int J Cardiol 2006;111: 442–9.
58. Bakshi TK, Choo MK, Edwards CC, et al. Causes of elevated troponin I with a normal coronary angiogram. Intern Med J 2002; 32:520 –5.
59. Kong TQ, Davidson CJ, Meyers SN, et al. Prognostic implication of creatine kinase elevation following elective coronary artery interven-tions. JAMA 1997;277:461– 6
60. Narins CR, Miller DP, Califf RM, et al. The relationship between periprocedural myocardial infarction and subsequent target vessel revascularization following percutaneous coronary revascularization: insights from the EPIC trial. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in preventing ischemic complications. J Am Coll Cardiol 1999;33:647–53.
61. Stone GW, Mehran R, Dangas G, et al. Differential impact on survival of electrocardiographic Q-wave versus enzymatic myocardial infarction after percutaneous intervention: a device-specific analysis of 7147 patients. Circulation 2001;104:642–7.
62. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011;58:e44 –122.
63. Cantor WJ, Newby LK, Christenson RH, et al. Prognostic significance of elevated troponin I after percutaneous coronary intervention. J Am Coll Cardiol 2002;39:1738 – 44.
64. Nageh T, Sherwood RA, Harris BM, et al. Prognostic role of cardiac troponin I after percutaneous coronary intervention in stable coronary disease. Heart 2005;91:1181–5.
65. Nienhuis MB, Ottervanger JP, Bilo HJ, et al. Prognostic value of troponin after elective percutaneous coronary intervention: a meta-analysis. Catheter Cardiovasc Interv 2008;71:318 –24.
66. Prasad A, Gersh BJ, Bertrand ME, et al. Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUITY (Acute Cathe-terization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol 2009;54:477– 86.
67. Ricciardi MJ, Davidson CJ, Gubernikoff G, et al. Troponin I elevation and cardiac events after percutaneous coronary intervention. Am Heart J 2003;145:522– 8.
68. Testa L, Van Gaal WJ, Biondi Zoccai GG, et al. Myocardial infarction after percutaneous coronary intervention: a meta-analysis of troponin elevation applying the new universal definition. QJM 2009;102:369 –78.
69. Miller WL, Garratt KN, Burritt MF, et al. Baseline troponin level: key to understanding the importance of post-PCI troponin eleva-tions. Eur Heart J 2006;27:1061–9.
70. Prasad A, Rihal CS, Lennon RJ, et al. Significance of periprocedural myonecrosis on outcomes after percutaneous coronary intervention: an analysis of preintervention and postintervention troponin T levels in 5487 patients. Circ Cardiovasc Interv 2008;1:10 –9.
71. Wu AH, Jaffe AS, Apple FS, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines: use of cardiac troponin and B-type natriuretic peptide or N-terminal proB-type natriuretic peptide for etiologies other than acute coronary syndromes and heart failure. Clin Chem 2007;53:2086 –96.
72. Silber S, Albertsson P, Aviles FF, et al., the Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Guidelines for percutaneous coronary interventions. Eur Heart J 2005;26:804 – 47.
73. Blankenship JC, Tasissa G, O’Shea JC, et al. Effect of glycoprote inIIb/IIIa receptor inhibition on angiographic complications during percutaneous coronary intervention in the ESPRIT trial. J Am Coll Cardiol 2001;38:653– 8.
74. De Gennaro GL, Brunetti ND, Cuculo A, et al. Increased troponin levels in nonischemic cardiac conditions and noncardiac diseases. J Interv Cardiol 2008;21:129 –39.
75. Fromm RE Jr. Cardiac troponins in the intensive care unit: common causes of increased levels and interpretation. Crit Care Med 2007; 35:584 – 8.
76. Jeremias A, Gibson CM. Narrative review: alternative causes for elevated cardiac troponin levels when acute coronary syndromes are excluded. Ann Intern Med 2005;142:786 –91.
77. Gupta S, de Lemos JA. Use and misuse of cardiac troponins in clinical practice. Prog Cardiovasc Dis 2007;50:151– 65.
78. Peacock WF 4th, De Marco T, Fonarow GC, et al., ADHERE Investigators. Cardiac troponin and outcome in acute heart failure. N Engl J Med 2008;358:2117–26.
79. Setsuta K, Seino Y, Ogawa T, et al. Use of cytosolic and myofibril markers in the detection of ongoing myocardial damage in patients with chronic heart failure. Am J Med 2002;113:717–22.
80. La Vecchia L, Mezzena G, Zanolla L, et al. Cardiac troponin I as diagnostic and prognostic marker in severe heart failure. J Heart Lung Transplant 2000;19:644 –52.
81. Ishii J, Cui W, Kitagawa F, et al. Prognostic value of combination of cardiac troponin T and B-type natriuretic peptide after initiation of treatment in patients with chronic heart failure. Clin Chem 2003;49: 2020 – 6.
82. Perna ER, Macin SM, Cimbaro Canella JP, et al. Minor myocardial damage detected by troponin T is a powerful predictor of long-term prognosis in patients with acute decompensated heart failure. Int J Cardiol 2005;99:253– 61.
83. Ilva T, Lassus J, Siirila-Waris K, et al. Clinical significance of cardiac troponins I and T in acute heart failure. Eur J Heart Fail 2008;10: 772–9.
84. Horwich TB, Patel J, MacLellan WR, et al. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation 2003;108:833– 8.
85. Miller WL, Hartman KA, Burritt MF, et al. Profiles of serial changes in cardiac troponin T concentrations and outcome in ambulatory patients with chronic heart failure. J Am Coll Cardiol 2009;54:1715–21.
86. Sato Y, Yamada T, Taniguchi R, et al. Persistently increased serum concentrations of cardiac troponin t in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes. Circula-tion 2001;103:369 –74.
87. Perna ER, Macin SM, Canella JP, et al. Ongoing myocardial injury in stable severe heart failure: value of cardiac troponin T monitoring for high-risk patient identification. Circulation 2004;110:2376 – 82.
88. Hudson MP, O’Connor CM, Gattis WA, et al. Implications of elevated cardiac troponin T in ambulatory patients with heart failure: a prospective analysis. Am Heart J 2004;147:546 –52.
89. Tang WH, Francis GS, Morrow DA, et al. National academy of clinical biochemistry laboratory medicine practice guidelines: clinical utilization of cardiac biomarker testing in heart failure. Circulation 2007;116:e99 –109.
90. Kociol RD, Pang PS, Gheorghiade M, et al. Troponin elevation in heart failure prevalence, mechanisms, and clinical implications. J Am Coll Cardiol 2010;56:1071– 8.
91. Becattini C, Vedovati MC, Agnelli G. Prognostic value of troponins in acute pulmonary embolism: a meta-analysis. Circulation 2007;116: 427–33.
92. Becattini C, Vedovati MC, Agnelli G. Diagnosis and prognosis of acute pulmonary embolism: focus on serum troponins. Expert Rev Mol Diagn 2008;8:339 – 49.
93. Kucher N, Rossi E, De Rossi M, Goldhaber SZ. Prognostic role of echocardiography among patients with acute pulmonary embolism and a systolic arterial pressure of 90 mm Hg or higher. Arch Intern Med 2005;165:1777– 81.
94. Fremont B, Pacouret G, Jacobi D, et al. Prognostic value of echocardiographic right/left ventricular end-diastolic diameter ratio in patients with acute pulmonary embolism: results from a mono-center registry of 1,416 patients. Chest 2008;133:358 – 62.
95. Toosi MS, Merlino JD, Leeper KV. Prognostic value of the shock index along with transthoracic echocardiography in risk stratification of patients with acute pulmonary embolism. Am J Cardiol 2008;101: 700 –5.
96. Zhu L, Yang Y, Wu Y, et al. Value of right ventricular dysfunction for prognosis in pulmonary embolism. Int J Cardiol 2008;127:40 –5.
97. Kreit JW. The impact of right ventricular dysfunction on the prognosis and therapy of normotensive patients with pulmonary embolism. Chest 2004;125:1539 – 45.
98. Goldhaber SZ, Visani L, DeRosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Em-bolism Registry (ICOPER). Lancet 1999;353:1386 –9.
99. ten Wolde M, Söhne M, Quak E, Mac Gillavry MR, Büller HR. Prognostic value of echocardiographically assessed right ventricular dysfunction in patients with pulmonary embolism. Arch Intern Med 2004;164:1685–9.
100. Gibson NS, Sohne M, Buller HR. Prognostic value of echocardiog-raphy and spiral computed tomography in patients with pulmonary embolism. Curr Opin Pulm Med 2005;11:380 – 4.
101. Konstantinides S. Pulmonary embolism: impact of right ventricular dysfunction. Curr Opin Cardiol 2005;20:496 –501.
102. Horlander KT, Leeper KV. Troponin levels as a guide to treatment of pulmonary embolism. Curr Opin Pulm Med 2003;9:374 –7.
103. Mikulewicz M, Lewczuk J. Importance of cardiac biomarkers in risk stratification in acute pulmonary embolism. Cardiol J 2008;15:17–20.
104. Giannitsis E, Muller-Bardorff M, Kurowski V, et al. Independent prognostic value of cardiac troponin T in patients with confirmed pulmonary embolism. Circulation 2000;102:211–7.
105. Meyer T, Binder L, Hruska N, et al. Cardiac troponin I elevation in acute pulmonary embolism is associated with right ventricular dys-function. J Am Coll Cardiol 2000;36:1632– 6.
106. Konstantinides S, Geibel A, Olschewski M, et al. Importance of cardiac troponins I and T in risk stratification of patients with acute pulmonary embolism. Circulation 2002;106:1263– 8.
107. Punukollu G, Khan IA, Gowda RM, et al. Cardiac troponin I release in acute pulmonary embolism in relation to the duration of symp-toms. Int J Cardiol 2005;99:207–11.
108. Aksay E, Yanturali S, Kiyan S. Can elevated troponin I levels predict complicated clinical course and inhospital mortality in patients with acute pulmonary embolism? Am J Emerg Med 2007;25:138 – 43.
109. Logeart D, Lecuyer L, Thabut G, et al. Biomarker-based strategy for screening right ventricular dysfunction in patients with non-massive pulmonary embolism. Intensive Care Med 2007;33:286 –92.
110. Kline JA, Zeitouni R, Marchick MR, et al. Comparison of 8 biomarkers for prediction of right ventricular hypokinesis 6 months after submassive pulmonary embolism. Am Heart J 2008;156: 308 –14.
111. Konstantinides S. Clinical practice: acute pulmonary embolism. N Engl J Med 2008;359: 2804 –13.
112. Tapson VF. Acute pulmonary embolism. N Engl J Med 2008;358: 1037–52.
113. Konstantinides S, Geibel A, Olschewski M, et al. Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism: results of a multicenter registry. Circulation 1997;96:882– 8.
114. Konstantinides S, Geibel A, Heusel G, et al. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 2002;347:1143–50.
115. Goldhaber SZ. Thrombolytic therapy for patients with pulmonary embolism who are hemodynamically stable but have right ventricular dysfunction: pro. Arch Intern Med 2005;165:2197–9.
116. Thabut G, Thabut D, Myers RP, et al. Thrombolytic therapy of pulmonary embolism: a meta-analysis. J Am Coll Cardiol 2002;40: 1660 –7.
117. Wan S, Quinlan DJ, Agnelli G, et al. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation 2004;110: 744 –9.
118. Thabut G, Logeart D. Thrombolysis for pulmonary embolism in patients with right ventricular dysfunction: con. Arch Intern Med 2005;165:2200 –3.
119. Dong B, Jirong Y, Liu G, et al. Thrombolytic therapy for pulmonary embolism. Cochrane Database Syst Rev 2006;CD004437.
120. Perlroth DJ, Sanders GD, Gould MK. Effectiveness and cost-effectiveness of thrombolysis in submassive pulmonary embolism. Arch Intern Med 2007;167:74 – 80.
121. Zamanian RT, Gould MK. Effectiveness and cost effectiveness of thrombolysis in patients with acute pulmonary embolism. Curr Opin Pulm Med 2008;14:422– 6.
122. Leacche M, Unic D, Goldhaber SZ, et al. Modern surgical treatment of massive pulmonary embolism: results in 47 consecutive patients after rapid diagnosis and aggressive surgical approach. J Thorac Cardiovasc Surg 2005;129:1018 –23.
123. Aklog L, Williams CS, Byrne JG, et al. Acute pulmonary embolec-tomy: a contemporary approach. Circulation 2002;105:1416 –9.
124. Kucher N, Goldhaber SZ. Cardiac biomarkers for risk stratification of patients with acute pulmonary embolism. Circulation 2003;108: 2191– 4.
125. Kanderian AS, Francis GS. Cardiac troponins and chronic kidney disease. Kidney Int 2006;69:1112– 4.
126. Wang AY, Lai KN. Use of cardiac biomarkers in end-stage renal disease. J Am Soc Nephrol 2008;19:1643–52.
127. Abbas NA, John RI, Webb MC, et al. Cardiac troponins and renal function in nondialysis patients with chronic kidney disease. Clin Chem 2005;51:2059 – 66.
128. Wang AY, Lam CW, Wang M, et al. Prognostic value of cardiac troponin T is independent of inflammation, residual renal function, and cardiac hypertrophy and dysfunction in peritoneal dialysis pa-tients. Clin Chem 2007;53:882–9.
129. Roberts MA, MacMillan N, Hare DL, et al. Cardiac troponin levels in asymptomatic patients on the renal transplant waiting list. Ne-phrology (Carlton) 2006;11:471– 6.
130. Möckel M, Schindler R, Knorr L, et al. Prognostic value of cardiac troponin T and I elevations in renal disease patients without acute coronary syndromes: a 9-month outcome analysis. Nephrol Dial Transplant 1999;14:1489 –95.
131. Wood GN, Keevil B, Gupta J, et al. Serum troponin T measurement in patients with chronic renal impairment predicts survival and vascular disease: a 2 year prospective study. Nephrol Dial Transplant 2003;18:1610 –5.
132. Havekes B, van Manen JG, Krediet RT, et al. Serum troponin T concentration as a predictor of mortality in hemodialysis and perito-neal dialysis patients. Am J Kidney Dis 2006;47:823–9.
133. Diris JH, Hackeng CM, Kooman JP, et al. Impaired renal clearance explains elevated troponin T fragments in hemodialysis patients. Circulation 2004;109:23–5.
134. Ellis K, Dreisbach AW, Lertora JL. Plasma elimination of cardiac troponin I in end-stage renal disease. South Med J 2001;94:993– 6.
135. Khan NA, Hemmelgarn BR, Tonelli M, et al. Prognostic value of troponin T and I among asymptomatic patients with end-stage renal disease: a meta-analysis. Circulation 2005; 112:3088 –96.
136. Sommerer C, Beimler J, Schwenger V, et al. Cardiac biomarkers and survival in haemodialysis patients. Eur J Clin Invest 2007; 37: 350 – 6.
137. Conway B, McLaughlin M, Sharpe P, et al. Use of cardiac troponin T in diagnosis and prognosis of cardiac events in patients on chronic haemodialysis. Nephrol Dial Transplant 2005;20:2759 – 64.
138. Abaci A, Ekici E, Oguzhan A, et al. Cardiac troponins T and I in patients with end-stage renal disease: the relation with left ventricular mass and their prognostic value. Clin Cardiol 2004; 27:704 –9.
139. Duman D, Tokay S, Toprak A, et al. Elevated cardiac troponin T is associated with increased left ventricular mass index and predicts mortality in continuous ambulatory peritoneal dialysis patients. Nephrol Dial Transplant 2005;20:962–7.
140. Connolly GM, Cunningham R, McNamee PT, et al. Troponin T is an independent predictor of mortality in renal transplant recipients. Nephrol Dial Transplant 2008; 23: 1019 –25.
141. Kanwar M, Hashem M, Rosman H, et al. Usefulness of clinical evaluation, troponins, and C-reactive protein in predicting mortality among stable hemodialysis patients. Am J Cardiol 2006; 98:1283–7.
142. K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005;45 Suppl 3:S1–153.
143. Favory R, Neviere R. Significance and interpretation of elevated troponin in septic patients. Crit Care 2006; 10:224 –9.
144. Maeder M, Fehr T, Rickli H, et al. Sepsis-associated myocardial dysfunction: diagnostic and prognostic impact of cardiac troponins and natriuretic peptides. Chest 2006; 129:1349 – 66.
145. Rudiger A, Singer M. Mechanisms of sepsis-induced cardiac dysfunction. Crit Care Med 2007; 35:1599 – 608.
146. Spies C, Haude V, Fitzner R, et al. Serum cardiac troponin T as a prognostic marker in early sepsis. Chest 1998; 113:1055– 63.
147. Fernandes CJ Jr., Akamine N, Knobel E. Cardiac troponin: a new serum marker of myocardial injury in sepsis. Intensive Care Med 1999;25:1165– 8.
148. Turner A, Tsamitros M, Bellomo R. Myocardial cell injury in septic shock. Crit Care Med 1999; 27:1775– 80.
149. Arlati S, Brenna S, Prencipe L, et al. Myocardial necrosis in ICU patients with acute non-cardiac disease: a prospective study. Intensive Care Med 2000; 26:31–7.
150. ver Elst KM, Spapen HD, Nguyen DN, et al. Cardiac troponins I and T are biological markers of left ventricular dysfunction in septic shock. Clin Chem 2000;46 :650 –7.
151. Ammann P, Fehr T, Minder EI, et al. Elevation of troponin I in sepsis and septic shock. Intensive Care Med 2001;27:965–9
152. Ammann P, Maggiorini M, Bertel O, et al. Troponin as a risk factor for mortality in critically ill patients without acute coronary syndromes. J Am Coll Cardiol 2003;41:2004 –9.
153. Mehta NJ, Khan IA, Gupta V, et al. Cardiac troponin I predicts myocardial dysfunction and adverse outcome in septic shock. Int J Cardiol 2004;95:13–7.
154. Kalla C, Raveh D, Algur N, et al. Incidence and significance of a positive troponin test in bacteremic patients without acute coronary syndrome. Am J Med 2008;121:909 –15.
155. Scott EC, Ho HC, Yu M, et al. Pre-existing cardiac disease, troponin I elevation and mortality in patients with severe sepsis and septic shock. Anaesth Intensive Care 2008;36:51–9.
156. Wallace KB, Hausner E, Herman E, et al. Serum troponins as biomarkers of drug-induced cardiac toxicity. Toxicol Pathol 2004;32: 106 –21.
157. Cardinale D, Sandri MT, Martinoni A, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 2000; 36:517–22.
158. Sandri MT, Cardinale D, Zorzino L, et al. Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy. Clin Chem 2003; 49:248 –52.
159. Auner HW, Tinchon C, Linkesch W, et al. Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann Hematol 2003;82:218 –22.
160. Missov E, Calzolari C, Davy JM, et al. Cardiac troponin I in patients with hematologic malignancies. Coron Artery Dis 1997;8:537– 41.
161. Cardinale D, Sandri MT, Martinoni A, et al. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol 2002;13:710 –5.
162. Kilickap S, Barista I, Akgul E, et al. cTnT can be a useful marker for early detection of anthracycline cardiotoxicity. Ann Oncol 2005; 16: 798 – 804.
163. Zver S, Zadnik V, Bunc M, et al. Cardiac toxicity of high-dose cyclophosphamide in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. Int J Hematol 2007; 85:408 –14.
164. Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004; 109:2749 –54.
165. Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006;114: 2474 – 81.
166. Fink FM, Genser N, Fink C, et al. Cardiac troponin T and creatine kinase MB mass concentrations in children receiving anthracycline chemotherapy. Med Pediatr Oncol 1995; 25:185–9.
167. Kismet E, Varan A, Ayabakan C, et al. Serum troponin T levels and echocardiographic evaluation in children treated with doxorubicin. Pediatr Blood Cancer 2004;42:220 – 4.
168. Germanakis I, Anagnostatou N, Kalmanti M. Troponins and natri-uretic peptides in the monitoring of anthracycline cardiotoxicity. Pediatr Blood Cancer 2008;51:327–33.
169. Newby LK, Rodriguez I, Finkle J, et al. Troponin measurements during drug development: considerations for monitoring and man-agement of potential cardiotoxicity. An educational collaboration among the Cardiac Safety Research Consortium, the Duke Clinical Research Institute, and the US Food and Drug Administration. Am Heart J 2011;162:64 –73.
170. Jaffe AS, Babuin L, Apple FS. Biomarkers in acute cardiac disease: the present and the future. J Am Coll Cardiol 2006;48:1–11.
171. Ellis CR, Di Salvo T. Myocarditis: basic and clinical aspects. Cardiol Rev 2007; 15:170 –7.
172. Pisani B, Taylor DO, Mason JW. Inflammatory myocardial diseases and cardiomyopathies. Am J Med 1997; 102:459 – 69.
173. Mason JW, O’Connell JB, Herskowitz A, et al., the Myocarditis Treatment Trial Investigators A clinical trial of immunosuppressive therapy for myocarditis. N Engl J Med 1995;333:269 –75.
174. Smith SC, Ladenson JH, Mason JW, et al. Elevations of cardiac troponin I associated with myocarditis: experimental and clinical correlates. Circulation 1997; 95:163– 8.
175. Matsumori A, Shimada T, Chapman NM, et al. Myocarditis and heart failure associated with hepatitis C virus infection. J Card Fail 2006;12:293– 8.
176. McNamara DM, Holubkov R, Starling RC, et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation 2001; 103:2254 –9.
177. Barbaro G. Cardiovascular manifestations of HIV infection.JRSoc Med 2001; 94: 384 –90.
178. Fish AE, Pride YB, Pinto DS. Lyme carditis. Infect Dis Clin North Am 2008; 22:275– 88, vi.
179. Pinto DS. Cardiac manifestations of Lyme disease. Med Clin North Am 2002; 86:285–96.
180. Khongphatthanayothin A, Lertsapcharoen P, Supachokchaiwattana P, et al. Myocardial depression in dengue hemorrhagic fever: preva-lence and clinical description. Pediatr Crit Care Med 2007; 8:524 –9.
181. Ehrhardt S, Wichmann D, Hemmer CJ, et al. Circulating concentrations of cardiac proteins in complicated and uncomplicated Plasmodium falciparum malaria. Trop Med Int Health 2004; 9:1099 –103.
182. Eckart RE, Love SS, Atwood JE, et al. Incidence and follow-up of inflammatory cardiac complications after smallpox vaccination. J Am Coll Cardiol 2004; 44:201–5.
183. Lalloo DG, Trevett AJ, Nwokolo N, et al. Electrocardiographic abnormalities in patients bitten by taipans (Oxyuranus scutellatus canni) and other elapid snakes in Papua New Guinea. Trans R Soc Trop Med Hyg 1997; 91:53– 6.
184. Cupo P, de Azevedo-Marques MM, Hering SE. Absence of myocardial involvement in children victims of Crotalus durissus terrificus envenoming. Toxicon 2003; 42:741–5.
185. Gaze DC, Collinson PO. Cardiac troponins as biomarkers of drug-and toxin-induced cardiac toxicity and cardioprotection. Expert Opin Drug Metab Toxicol 2005; 1:715–25.
186. Tavli V, Canbal A, Saylan B, et al. Assessment of myocardial involvement using cardiac troponin-I and echocardiography in rheumatic carditis in Izmir, Turkey. Pediatr Int 2008; 50:62– 4.
187. Alehan D, Ayabakan C, Hallioglu O. Role of serum cardiac troponin T in the diagnosis of acute rheumatic fever and rheumatic carditis. Heart 2004; 90:689 –90.
188. Oran B, Coban H, Karaaslan S, et al. Serum cardiac troponin-I in active rheumatic carditis. Indian J Pediatr 2001; 68:943– 4.
189. Kamblock J, Payot L, Iung B, et al. Does rheumatic myocarditis really exist? Systematic study with echocardiography and cardiac troponin I blood levels. Eur Heart J 2003;24:855– 62.
190. Gupta M, Lent RW, Kaplan EL, et al. Serum cardiac troponin I in acute rheumatic fever. Am J Cardiol 2002; 89:779 – 82.
191. Brandt RR, Filzmaier K, Hanrath P. Circulating cardiac troponin I in acute pericarditis. Am J Cardiol 2001; 87:1326 – 8.
192. Bonnefoy E, Godon P, Kirkorian G, et al. Serum cardiac troponin I and ST-segment elevation in patients with acute pericarditis. Eur Heart J 2000; 21:832– 6.
193. Imazio M, Cecchi E, Demichelis B, et al. Indicators of poor prognosis of acute pericarditis. Circulation 2007; 115:2739 – 44.
194. Imazio M, Demichelis B, Cecchi E, et al. Cardiac troponin I in acute pericarditis. J Am Coll Cardiol 2003; 42:2144 – 8.
195. Selvanayagam JB, Hawkins PN, Paul B, et al. Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol 2007; 50: 2101–10.
196. Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004; 22:3751–7.
197. Lebovic D, Hoffman J, Levine BM, et al. Predictors of survival in patients with systemic light-chain amyloidosis and cardiac in-volvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone. Br J Haematol 2008;143:369 –73.
198. Miller WL, Wright RS, McGregor CG, et al. Troponin levels in patients with amyloid cardiomyopathy undergoing cardiac transplan-tation. Am J Cardiol 2001; 88:813–5.
199. Kristen AV, Meyer FJ, Perz JB, et al. Risk stratification in cardiac amyloidosis: novel approaches. Transplantation 2005; 80:S151–S155.
200. Dispenzieri A, Gertz MA, Kyle RA, et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2004; 104:1881–7.
201. Suhr OB, Anan I, Backman C, et al. Do troponin and B-natriuretic peptide detect cardiomyopathy in transthyretin amyloidosis? J Intern Med 2008; 263:294 –301.
202. Gertz M, Lacy M, Dispenzieri A, et al. Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amy-loidosis. Leuk Lymphoma 2008; 49:36 – 41.
203. Zimmermann R, Baki S, Dengler TJ, et al. Troponin T release after heart transplantation. Br Heart J 1993; 69:395– 8.
204. Hokl J, Cerny J, Nemec P, et al. Serum troponin T in the early posttransplant period and long-term graft function in heart recipi-ents. Transplant Proc 2001; 33:2018 –9.
205. Biagioli B, Simeone F, Marchetti L, et al. Graft functional recovery and outcome after heart transplant: is troponi n I a reliable marker? Transplant Proc 2003; 35:1519 –22.
206. Dengler TJ, Gleissner CA, Klingenberg R, et al. Biomarkers after heart transplantation: nongenomic. Heart Fail Clin 2007; 3:69 – 81.
207. Alexis JD, Lao CD, Selter JG, et al. Cardiac troponin T: a noninvasive marker for heart transplant rejection? J Heart Lung Transplant 1998; 17:395– 8.
208. Mullen JC, Bentley MJ, Scherr KD, et al. Troponin T and I are not reliable markers of cardiac transplant rejection. Eur J Cardiothorac Surg 2002; 22:233–7.
209. Wang CW, Steinhubl SR, Castellani WJ, et al. Inability of serum myocyte death markers to predict acute cardiac allograft rejection. Transplantation 1996; 62:1938 – 41.
210. Dengler TJ, Zimmermann R, Braun K, et al. Elevated serum concentrations of cardiac troponin T in acute allograft rejection after human heart transplantation. J Am Coll Cardiol 1998; 32:405–12.
211. Chance JJ, Segal JB, Wallerson G, et al. Cardiac troponin T and C-reactive protein as markers of acute cardiac allograft rejection. Clin Chim Acta 2001; 312:31–9.
212. Gleissner CA, Zehelein J, Sack FU, et al. Extended experience and subgroup analysis using cardiac troponin T for rejection monitoring after heart transplantation. Transplant Proc 2002; 34:2178 – 80.
213. Gleissner CA, Klingenberg R, Nottmeyer W, et al. Diagnostic efficiency of rejection monitoring after heart transplantation with cardiac troponin T is improved in specific patient subgroups. Clin Transplant 2003;17:284 –91.
214. Faulk WP, Labarrere CA, Torry RJ, et al. Serum cardiac troponin-T concentrations predict development of coronary artery disease in heart transplant patients. Transplantation 1998; 66:1335–9.
215. Labarrere CA, Nelson DR, Cox CJ, et al. Cardiac-specific troponin I levels and risk of coronary artery disease and graft failure following heart transplantation. JAMA 2000; 284:457– 64.
216. El-Chami MF, Nicholson W, Helmy T. Blunt cardiac trauma. J Emerg Med 2008; 35:127–33.
217. Sybrandy KC, Cramer MJ, Burgersdijk C. Diagnosing cardiac contusion: old wisdom and new insights. Heart 2003; 89:485–9.
218. Gunnewiek JM, Van Der Hoeven JG. Cardiac troponin elevations among critically ill patients. Curr Opin Crit Care 2004; 10:342– 6.
219. Kaye P, O’Sullivan I. Myocardial contusion: emergency investigation and diagnosis. Emerg Med J 2002; 19:8 –10.
220. Riou B. Troponin: important in severe trauma and a first step in the biological marker revolution. Anesthesiology 2004; 101:1259 – 60.
221. Swaanenburg JC, Klaase JM, DeJongste MJ, et al. Troponin I, troponin T, CKMB-activity and CKMB-mass as markers for the detection of myocardial contusion in patients who experienced blunt trauma. Clin Chim Acta 1998; 272:171– 81.
222. Bertinchant JP, Polge A, Mohty D, et al. Evaluation of incidence, clinical significance, and prognostic value of circulating cardiac troponin I and T elevation in hemodynamically stable patients with suspected myocardial contusion after blunt chest trauma. J Trauma 2000; 48:924 –31.
223. Martin M, Mullenix P, Rhee P, et al. Troponin increases in the critically injured patient: mechanical trauma or physiologic stress? J Trauma 2005; 59:1086 –91.
224. Adams JE III, Davila-Roman VG, Bessey PQ, et al. Improved detection of cardiac contusion with cardiac troponin I. Am Heart J 1996;131:308 –12.
225. Collins JN, Cole FJ, Weireter LJ, et al. The usefulness of serum troponin levels in evaluating cardiac injury. Am Surg 2001;67:821–5.
226. Velmahos GC, Karaiskakis M, Salim A, et al. Normal electrocardiography and serum troponin I levels preclude the presence of clinically significant blunt cardiac injury. J Trauma 2003; 54:45–50.
227. Rajan GP, Zellweger R. Cardiac troponin I as a predictor of arrhythmia and ventricular dysfunction in trauma patients with myocardial contusion. J Trauma 2004; 57:801– 8.
228. Edouard AR, Felten ML, Hebert JL, et al. Incidence and significance of cardiac troponin I release in severe trauma patients. Anesthesiology 2004; 101:1262– 8.
229. Chan MY, Pronovost PJ. Clinical utility of biomarkers in myocardial injury. Curr Opin Anaesthesiol 2004; 17:49 –55.
230. Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). J Am Coll Cardiol 2007;50:e159 –241.
231. Sametz W, Metzler H, Gries M, et al. Perioperative catecholamine changes in cardiac risk patients. Eur J Clin Invest 1999; 29:582–7.
232. Oscarsson A, Eintrei C, Anskar S, et al. Troponin T-values provide long-term prognosis in elderly patients undergoing non-cardiac surgery. Acta Anaesthesiol Scand 2004; 48:1071–9.
233. Kertai MD, Boersma E, Klein J, et al. Long-term prognostic value of asymptomatic cardiac troponin T elevations in patients after major vascular surgery. Eur J Vasc Endovasc Surg 2004; 28:59 – 66.
234. Lopez-Jimenez F, Goldman L, Sacks DB, et al. Prognostic value of cardiac troponin T after noncardiac surgery: 6-month follow-up data. J Am Coll Cardiol 1997; 29:1241–5.
235. Relos RP, Hasinoff IK, Beilman GJ. Moderately elevated serum troponin concentrations are associated with increased morbidity and mortality rates in surgical intensive care unit patients. Crit Care Med 2003; 31: 2598 – 603.
236. Kim LJ, Martinez EA, Faraday N, et al. Cardiac troponin I predicts short-term mortality in vascular surgery patients. Circulation 2002; 106:2366 –71.
237. Horton JW, Garcia NM, White DJ, et al. Postburn cardiac contractile function and biochemical markers of postburn cardiac injury. J Am Coll Surg 1995; 181:289 –98.
238. Chen YN, Luo ZR, Zeng LJ, et al. Cardiac troponin I: a marker for post-burn cardiac injury. Ann Clin Biochem 2000; 37 (Pt 4):447–51.
239. Murphy JT, Horton JW, Purdue GF, et al. Evaluation of troponin-I as an indicator of cardiac dysfunction after thermal injury. J Trauma 1998;45:700 – 4.
240. Jensen JK, Bak S, Flemming Hoilund-Carlsen P, et al. Prevalence of electrocardiographic ST-T changes during acute ischemic stroke in patients without known ischemic heart disease. Int J Cardiol 2008; 128: 137– 8.
241. Khechinashvili G, Asplund K. Electrocardiographic changes in patients with acute stroke: a systematic review. Cerebrovasc Dis 2002; 14:67–76.
242. Kopelnik A, Zaroff JG. Neurocardiogenic injury in neurovascular disorders. Crit Care Clin 2006;22: 733–52.
243. Naidech AM, Kreiter KT, Janjua N, et al. Cardiac troponin elevation, cardiovascular morbidity, and outcome after subarachnoid hemor-rhage. Circulation 2005;112: 2851– 6.
244. Zaroff JG, Pawlikowska L, Miss JC, et al. Adrenoceptor polymor-phisms and the risk of cardiac injury and dysfunction after subarach-noid hemorrhage. Stroke 2006; 37:1680 –5.
245. Yarlagadda S, Rajendran P, Miss JC, et al. Cardiovascular predictors of in-patient mortality after subarachnoid hemorrhage. Neurocrit Care 2006; 5:102–7.
246. Lee VH, Oh JK, Mulvagh SL, et al. Mechanisms in neurogenic stress cardiomyopathy after aneurysmal subarachnoid hemorrhage. Neuro-crit Care 2006; 5:243–9.
247. Lee VH, Connolly HM, Fulgham JR, et al. Tako-tsubo cardiomyopathy in aneurysmal subarachnoid hemorrhage: an underappreciated ventricular dysfunction. J Neurosurg 2006; 105:264 –70.
248. Mayer SA, Lin J, Homma S, et al. Myocardial injury and left ventricular performance after subarachnoid hemorrhage. Stroke 1999; 30:780 – 6.
249. Jensen JK, Atar D, Mickley H. Mechanism of troponin elevations in patients with acute ischemic stroke. Am J Cardiol 2007; 99:867–70.
250. Jespersen CM, Fischer HJ. Myocardial stress in patients with acute cerebrovascular events. Cardiology 2008; 110:123– 8.
251. Parekh N, Venkatesh B, Cross D, et al. Cardiac troponin I predicts myocardial dysfunction in aneurysmal subarachnoid hemorrhage. J Am Coll Cardiol 2000; 36:1328 –35.
252. Chalela JA, Ezzeddine MA, Davis L, et al. Myocardial injury in acute stroke: a troponin I study. Neurocrit Care 2004; 1:343– 6.
253. Di Angelantonio E, Fiorelli M, Toni D, et al. Prognostic significance of admission levels of troponin I in patients with acute ischaemic stroke. J Neurol Neurosurg Psychiatry 2005; 76:76 – 81.
254. Ay H, Arsava EM, Saribas O. Creatine kinase-MB elevation after stroke is not cardiac in origin: comparison with troponin T levels. Stroke 2002; 33:286 –9.
255. Jensen JK, Kristensen SR, Bak S, et al. Frequency and significance of troponin T elevation in acute ischemic stroke. Am J Cardiol 2007; 99:108 –12.
256. Sandhu R, Aronow WS, Rajdev A, et al. Relation of cardiac troponin I levels with in-hospital mortality in patients with ischemic stroke, intracerebral hemorrhage, and subarachnoid hemorrhage. Am J Cardiol 2008; 102:632– 4.
257. Christensen H, Johannesen HH, Christensen AF, et al. Serum cardiac troponin I in acute stroke is related to serum cortisol and TNF-alpha. Cerebrovasc Dis 2004; 18:194 –9.
258. James P, Ellis CJ, Whitlock RM, et al. Relation between troponin T concentration and mortality in patients presenting with an acute stroke: observational study. BMJ 2000; 320:1502– 4.
259. Fure B, Bruun WT, Thommessen B. Electrocardiographic and troponin T changes in acute ischaemic stroke. J Intern Med 2006; 259:592–7.
260. Hays A, Diringer MN. Elevated troponin levels are associated with higher mortality following intracerebral hemorrhage. Neurology 2006; 66:1330 – 4.
261. Watkin RW, Lang S, Smith JM, et al. Role of troponin I in active infective endocarditis. Am J Cardiol 2004; 94:1198 –9.
262. Purcell JB, Patel M, Khera A, et al. Relation of troponin elevation to outcome in patients with infective endocarditis. Am J Cardiol 2008; 101:1479 – 81.
263. Tsenovoy P, Aronow WS, Joseph J, et al. Patients with infective endocarditis and increased cardiac troponin I levels have a higher incidence of in-hospital mortality and valve replacement than those with normal cardiac troponin I levels. Cardiology 2009; 112:202– 4.
264. Alhakeem M, Arabi A, Arab L, et al. Unusual sites of metastatic involvement: intracardiac metastasis from laryngeal carcinoma. Eur J Echocardiogr 2008; 9:323–5.
265. Lewis CM. Clinical presentation and investigation of cardiac tumors. Semin Diagn Pathol 2008;25:65– 8.
266. Ekmektzoglou KA, Samelis GF, Xanthos T. Heart and tumors: location, metastasis, clinical manifestations, diagnostic approaches and therapeutic considerations. J Cardiovasc Med (Hagerstown) 2008; 9:769 –77.
267. Bussani R, De-Giorgio F, Abbate A, et al. Cardiac metastases. J Clin Pathol 2007; 60:27–34.
268. Neragi-Miandoab S, Kim J, Vlahakes GJ. Malignant tumours of the heart: a review of tumour type, diagnosis and therapy. Clin Oncol (R Coll Radiol) 2007; 19:748 –56.
269. Butany J, Nair V, Naseemuddin A, et al. Cardiac tumours: diagnosis and management. Lancet Oncol 2005;6: 219 –28.
270. Burke A. Primary malignant cardiac tumors. Semin Diagn Pathol 2008; 25:39 – 46.
271. Burke A, Jeudy J Jr., Virmani R. Cardiac tumours: an update: cardiac tumours. Heart 2008; 94:117–23.
272. Vaideeswar P, Butany JW. Benign cardiac tumors of the pluripotent mesenchyme. Semin Diagn Pathol 2008; 25:20 – 8.
273. Gotlieb AI. Cardiac fibromas. Semin Diagn Pathol 2008; 25:17–9.
274. Shanmugam G. Primary cardiac sarcoma. Eur J Cardiothorac Surg 2006; 29:925–32.
275. Luk A, Ahn E, Vaideeswar P, et al. Pericardial tumors. Semin Diagn Pathol 2008; 25:47–53.
276. Miller DV, Edwards WD. Cardiovascular tumor-like conditions. Semin Diagn Pathol 2008; 25:54 – 64.
277. Hohman DW, Noghrehkar D, Ratnayake S. Lymphangioleiomyo-matosis: A review. Eur J Intern Med 2008; 19:319 –24.
278. Pantanowitz L, Dezube BJ. Kaposi sarcoma in unusual locations. BMC Cancer 2008;8:190.
279. Agewall S. Increases of creatine kinase MB and cardiac troponin T in serum of a patient with uterine leiomyosarcoma. Clin Chem 2000;  46:2016 –7.
280. Isotalo PA, Greenway DC, Donnelly JG. Metastatic alveolar rhabdomyosarcoma with increased serum creatine kinase MB and cardiac troponin T and normal cardiac troponin I. Clin Chem 1999; 45: 1576 – 8.
281. Bhattacharyya S, Davar J, Dreyfus G, et al. Carcinoid heart disease. Circulation 2007;116:2860 –5.
282. Meijer WG, Swaanenburg JC, van Veldhuisen D, Kema IP, Willemse PH, de Vries EG. Troponin I, troponin T, and creatine kinase-MB mass in patients with the carcinoid syndrome with and without heart failure. Clin Chem 1999; 45:2296 –7.
283. Sato Y, Taniguchi R, Yamada T, et al. Measurement of serum concentrations of cardiac troponin T in patients with hypereosinophilic syndrome: a sensitive non-invasive marker of cardiac disorder. Intern Med 2000;39:350.
284. McCarthy LJ, Danielson CF, Skipworth EM, et al. Myocardial infarction/injury is relatively common at presentation of acute throm-botic thrombocytopenic purpura: the Indiana University experience. Ther Apher 2002; 6:2– 4.
285. Patschan D, Witzke O, Duhrsen U, et al. Acute myocardial infarction in thrombotic microangiopathies— clinical characteristics, risk factors and outcome. Nephrol Dial Transplant 2006; 21: 1549 –54.
286. Sakha K, Samadi M, Rezamand A. Cardiac involvement of major thalassemia and evaluation of total serum creatine kinase and creatine kinase-mB isoenzyme and cardiac troponinI in these patients. Pak J Biol Sci 2008; 11:1059 – 62.
287. Aslam AK, Rodriguez C, Aslam AF, et al. Cardiac troponin I in sickle cell crisis. Int J Cardiol 2009; 133:138 –9.
288. Lippi G, De Franceschi L, Salvagno GL, Pavan C, Mon